Developer docs
API playgroundTry for free, no card

Search company profiles

EditForce

Full company profile

uuid0002zcq

Namestring
EditForce
Legal namestring
エディットフォース株式会社
Websiteurl
editforce.co.jp
Company typeenum
Private
Founded yearint
2015
Descriptiontext

EditForce is a Japanese biopharmaceutical company founded in May 2015 and headquartered in Fukuoka that develops programmable RNA editing technologies based on pentatricopeptide repeat (PPR) proteins, licensed exclusively from Kyushu University (RNA applications, January 2016) and Hiroshima University (DNA applications, July 2016). The company's core platform exploits the inherent sequence-specific RNA-binding properties of PPR proteins, where each 35-amino-acid motif recognizes a single nucleotide and multiple motifs can be linked to target arbitrary RNA sequences without guide RNA. This architecture has been extended into multiple therapeutic modalities, including C-to-U RNA base editing via the RECODE technology (PPR-DYW fusion), the world's first U-to-C RNA editing demonstrated in human cells, PPR-directed exon skipping, and PPR-mediated translational enhancement. EditForce's lead drug candidate, EF-210, is a recombinant AAV-delivered CUG-PPR1 therapeutic for Myotonic Dystrophy Type 1 (DM1), with proof of concept completed in DM1 mouse models and IND filing planned for early 2027.

The company operates a hybrid business model combining proprietary drug development with platform licensing and co-development partnerships. Revenue is generated through bespoke licensing agreements (e.g., the June 2022 license to Tanabe Mitsubishi Pharma for CNS disease gene therapy drugs), co-development arrangements with partners such as Solasia Pharma (cancer, December 2019) and Japan Innovation Pharmaceutical (age-related macular degeneration, July 2018), and potential future product revenue from clinical-stage programs. Pricing is not publicly disclosed, as deals are negotiated individually with enterprise pharmaceutical counterparties. The go-to-market motion is enterprise field sales targeting pharmaceutical companies for licensing and co-development, supplemented by scientific publication in high-impact journals and media coverage (including an NHK World Science View feature in November 2025) to build credibility. Marketing is primarily through peer-reviewed publications, presentations at conferences such as ASGCT and World Muscle Society, and earned media in Japanese national outlets.

EditForce is venture-backed, having raised approximately 4.27 billion JPY cumulatively through rounds in 2019 (870M JPY Series B), 2021 (1.3B JPY across two rounds), and 2023 (2.1B JPY across two rounds), with major shareholders including KISCO, UTEC (University of Tokyo Edge Capital Partners), Newton Biocapital I (Belgium), Itochu Technology Ventures, MP Healthcare Venture Management (Mitsubishi Tanabe Pharma's CVC), and regional Japanese investors. The company has secured multiple non-dilutive AMED grants, was selected for the J-Startup KYUSHU program (2024) and recognized in the UK Government's National Vision for Engineering Biology publication (2023), and operates with 11-50 employees across Fukuoka R&D facilities (co-located at Kyushu University) and a Tokyo office. The company's competitive positioning is anchored by exclusive platform IP, multiple world-first scientific achievements, and a clear lead asset pathway toward clinical development.

Short descriptiontext

EditForce is a Fukuoka-based Japanese biotech developing programmable PPR protein-based RNA editing technologies for drug discovery. It licenses its platform to pharmaceutical partners and is advancing lead candidate EF-210 for Myotonic Dystrophy Type 1 toward IND filing in 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersFukuoka, Japan
HQ citystring
Fukuoka
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA editing technology, biopharmaceutical drug development, PPR protein platform, gene therapy therapeutics, rare disease treatment
Industry4 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
RNA Editing Therapeutics & Biopharmaceutical Drug Development
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Co-development Revenue
TypeLicensing Royalties
Description

Revenue generated from licensing PPR platform technology to pharmaceutical companies for specific disease applications, combined with co-development arrangements where EditForce contributes its technology platform and receives development milestones and royalties.

editforce.co.jp
2PPR Platform Technology Provision
TypeProfessional Services
Description

Platform technology provision and research services using proprietary PPR protein design capabilities, targeting pharmaceutical and biotech partners across drug discovery applications.

editforce.co.jp
3Drug Development Pipeline
TypeSubscription Recurring
Description

Proprietary drug development programs (e.g., EF-210 for DM1) progressed toward clinical stage, with potential for future product revenue upon regulatory approval.

editforce.co.jp
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

EditForce develops and licenses a proprietary PPR (Pentatricopeptide Repeat) protein-based platform technology for programmable RNA editing and manipulation. The platform enables sequence-specific RNA targeting, base editing (C-to-U and U-to-C), exon skipping, and translational enhancement, and is applied to pharmaceutical drug development (lead program EF-210 for Myotonic Dystrophy Type 1), agricultural seed development, and other biotechnology applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • EF-210: Single IV dose in DM1 mouse model achieved maximum efficacy (no muscle stiffness observed even after 20 needle insertions) at doses of 1×10^13 vg/kg or higher (Day 56)
+2 more records
Product overview1 text field

EditForce is a biopharmaceutical company developing PPR (pentatricopeptide repeat) protein-based RNA editing technologies. The company's core product is the PPR Platform Technology, a programmable RNA editing system that enables sequence-specific binding to target RNA. This platform supports multiple therapeutic approaches including the RECODE technology for C-to-U editing, U-to-C editing technology, and the lead drug candidate EF-210 for Myotonic Dystrophy Type 1 (DM1) treatment using the CUG-PPR1 molecule delivered via AAV vectors.

Product and service3 records
1PPR Platform Technology
CategoryRNA Editing Platform Technology
Description

A programmable RNA editing platform based on PPR proteins that enables sequence-specific binding to target RNA. Supports multiple RNA manipulation modes including RNA binding, C-to-U base editing (RECODE), U-to-C editing, exon skipping, and translational enhancement from a single-protein architecture. Licensed to pharmaceutical companies for drug development.

2RECODE Technology (RNA Editor for C-to-U with an Optimized DYW Enzyme)
CategoryRNA Base Editing Technology
Description

A proprietary C-to-U RNA editing technology combining a PPR protein that specifically binds to target RNA sequences with a DYW enzyme domain that converts cytidine (C) to uridine (U) in a single protein design. Enables precise base editing in animal cells and mice.

3EF-210
CategoryGene Therapy Drug Candidate
Description

Lead drug candidate: a recombinant AAV-based gene therapy for Myotonic Dystrophy Type 1 (DM1). Uses the CUG-PPR1 molecule that specifically binds to pathogenic CUG repeat RNA and blocks MBNL protein sequestration, restoring normal splicing activity and muscle function. Single IV dose demonstrated long-term efficacy in DM1 mouse model.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1国立研究開発法人日本医療研究開発機構 (AMED)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-22
Description

AMED (Japan Agency for Medical Research and Development) supports EditForce's drug development programs. EF-210 (DM1 treatment) was selected for AMED's 'Drug Discovery Venture Ecosystem Strengthening Project' (March 2023). Also selected in 2021 for 'RNA-targeted Drug Discovery Technology Development' under the Next-Generation Treatment/Diagnosis Realization Project.

editforce.co.jp
2田辺三菱製薬株式会社 (Tanabe Mitsubishi Pharma)
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-06-27
Description

License agreement signed in June 2022 granting Tanabe Mitsubishi Pharma rights to research, develop, and commercialize gene therapy drugs using EditForce's PPR protein platform for specific CNS diseases. Combines EditForce's bio-pharmaceutical engineering capabilities with Tanabe Mitsubishi's global drug development expertise.

editforce.co.jp
3ソレイジア・ファーマ株式会社 (Solasia Pharma)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-12-26
Description

Joint R&D agreement signed December 2019 for developing RNA editing-based cancer therapeutics. EditForce contributes PPR platform technology while Solasia contributes cancer drug development expertise. Multiple projects targeting different disease areas, RNA target sequences, and mechanisms of action.

editforce.co.jp
4日本革新創薬株式会社 (Japan Innovation Pharmaceutical)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-07-11
Description

Joint research agreement for age-related macular degeneration (AMD) drug development. EditForce designs and evaluates PPR proteins; Japan Innovation Pharmaceutical conducts animal model validation studies.

editforce.co.jp
5広島大学 (Hiroshima University)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2016-07-01
Description

Licensed DNA-targeting PPR technology from Hiroshima University (July 2016), providing EditForce with exclusive rights for DNA applications of PPR proteins, complementing the RNA rights from Kyushu University.

editforce.co.jp
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-12-01
Description

Founding partner institution. EditForce was established based on PPR protein research from Kyushu University Professor Takahiro Nakamura's laboratory. Signed joint research contract (December 2015) and exclusive patent license agreement (January 2016) for RNA PPR technology. Multiple co-development programs ongoing, including RECODE technology, EF-210, and structural studies published in Nature Communications (2026).

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage RNA editing company developing Axiomer RNA base-editing technology using ADAR enzymes. Targets similar genetic disease indications with platform approach, making it a direct competitor in programmable RNA editing therapeutics.

TypeDirect peer
Description

Clinical-stage RNA editing company using PRISM platform for oligonucleotide-based RNA base editing. Competes with EditForce in RNA-targeted therapeutics for genetic diseases, including neuromuscular disorders.

TypeDirect peer
Description

Clinical-stage RNA editing company using ADAR-mediated RNA editing (OPERA platform). Targets liver and CNS indications with similar programmable RNA editing approach to EditForce's PPR technology.

TypeEmerging player
Description

Emerging RNA editing company developing ADAR-based RNA editing therapeutics for genetic diseases. Competes with EditForce in the RNA editing modality with focus on liver-directed applications.

TypeEmerging player
Description

RNA editing company using RNA exon editing to address genetic diseases, including ophthalmology indications. Competes with EditForce's PPR-based exon skipping approach for genetic disease therapy.

TypeBroad incumbent
Description

Clinical-stage base editing company with broader portfolio including DNA base editing and RNA base editing. While focused on DNA editing, their RNA editing programs compete with EditForce's PPR platform for partner and investor attention.

TypeEmerging player
Description

RNA editing company using ADAR-based RNAfix platform and AAV delivery for in vivo RNA editing. Competes with EditForce in programmable RNA editing with similar AAV-delivery approach.

8Locanabio
TypeEmerging player
Description

RNA-targeted therapeutic company developing RNA editing and RNA-binding protein-based therapies for genetic diseases. Overlaps with EditForce in programmable RNA-targeting approach for neuromuscular and rare diseases.

9Mitsubishi Tanabe Pharma
TypeBroad incumbent
Description

Major Japanese pharmaceutical company and EditForce's CNS disease partner. Both share strategic interest in CNS and rare disease drug development using PPR platform, making it a strategic incumbent comparator.

TypeRegional player
Description

Japanese specialty pharma company and EditForce's cancer co-development partner. Comparable as a Japan-focused pharma developing RNA editing-based cancer therapeutics using PPR platform technology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EditForce

RNA Editing Therapeutics & Biopharmaceutical Drug Developmenteditforce.co.jp

EditForce is a Fukuoka-based Japanese biotech developing programmable PPR protein-based RNA editing technologies for drug discovery. It licenses its platform to pharmaceutical partners and is advancing lead candidate EF-210 for Myotonic Dystrophy Type 1 toward IND filing in 2027.

What EditForce does

EditForce is a Japanese biopharmaceutical company founded in May 2015 and headquartered in Fukuoka that develops programmable RNA editing technologies based on pentatricopeptide repeat (PPR) proteins, licensed exclusively from Kyushu University (RNA applications, January 2016) and Hiroshima University (DNA applications, July 2016). The company's core platform exploits the inherent sequence-specific RNA-binding properties of PPR proteins, where each 35-amino-acid motif recognizes a single nucleotide and multiple motifs can be linked to target arbitrary RNA sequences without guide RNA. This architecture has been extended into multiple therapeutic modalities, including C-to-U RNA base editing via the RECODE technology (PPR-DYW fusion), the world's first U-to-C RNA editing demonstrated in human cells, PPR-directed exon skipping, and PPR-mediated translational enhancement. EditForce's lead drug candidate, EF-210, is a recombinant AAV-delivered CUG-PPR1 therapeutic for Myotonic Dystrophy Type 1 (DM1), with proof of concept completed in DM1 mouse models and IND filing planned for early 2027.

The company operates a hybrid business model combining proprietary drug development with platform licensing and co-development partnerships. Revenue is generated through bespoke licensing agreements (e.g., the June 2022 license to Tanabe Mitsubishi Pharma for CNS disease gene therapy drugs), co-development arrangements with partners such as Solasia Pharma (cancer, December 2019) and Japan Innovation Pharmaceutical (age-related macular degeneration, July 2018), and potential future product revenue from clinical-stage programs. Pricing is not publicly disclosed, as deals are negotiated individually with enterprise pharmaceutical counterparties. The go-to-market motion is enterprise field sales targeting pharmaceutical companies for licensing and co-development, supplemented by scientific publication in high-impact journals and media coverage (including an NHK World Science View feature in November 2025) to build credibility. Marketing is primarily through peer-reviewed publications, presentations at conferences such as ASGCT and World Muscle Society, and earned media in Japanese national outlets.

EditForce is venture-backed, having raised approximately 4.27 billion JPY cumulatively through rounds in 2019 (870M JPY Series B), 2021 (1.3B JPY across two rounds), and 2023 (2.1B JPY across two rounds), with major shareholders including KISCO, UTEC (University of Tokyo Edge Capital Partners), Newton Biocapital I (Belgium), Itochu Technology Ventures, MP Healthcare Venture Management (Mitsubishi Tanabe Pharma's CVC), and regional Japanese investors. The company has secured multiple non-dilutive AMED grants, was selected for the J-Startup KYUSHU program (2024) and recognized in the UK Government's National Vision for Engineering Biology publication (2023), and operates with 11-50 employees across Fukuoka R&D facilities (co-located at Kyushu University) and a Tokyo office. The company's competitive positioning is anchored by exclusive platform IP, multiple world-first scientific achievements, and a clear lead asset pathway toward clinical development.

EditForce firmographics

Firmographics
Name
EditForce
Legal name
エディットフォース株式会社
Website
https://editforce.co.jp
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
EditForce is a Fukuoka-based Japanese biotech developing programmable PPR protein-based RNA editing technologies for drug discovery. It licenses its platform to pharmaceutical partners and is advancing lead candidate EF-210 for Myotonic Dystrophy Type 1 toward IND filing in 2027.
Ownership category
akta.pro rank

EditForce industry classification

Industry
Product category
RNA Editing Therapeutics & Biopharmaceutical Drug Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • RNA editing technology
  • Biopharmaceutical drug development
  • PPR protein platform
  • Gene therapy therapeutics
  • Rare disease treatment

Where EditForce is headquartered

Location

Headquarters

HQ city
Fukuoka
HQ country
Japan
HQ region
Asia

Offices3 records

Markets served

EditForce business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Co-development Revenue: Revenue generated from licensing PPR platform technology to pharmaceutical companies for specific disease applications, combined with co-development arrangements where EditForce contributes its technology platform and receives development milestones and royalties.
  2. PPR Platform Technology Provision: Platform technology provision and research services using proprietary PPR protein design capabilities, targeting pharmaceutical and biotech partners across drug discovery applications.
  3. Drug Development Pipeline: Proprietary drug development programs (e.g., EF-210 for DM1) progressed toward clinical stage, with potential for future product revenue upon regulatory approval.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

EditForce product offering

Product offering

Core offering

EditForce develops and licenses a proprietary PPR (Pentatricopeptide Repeat) protein-based platform technology for programmable RNA editing and manipulation. The platform enables sequence-specific RNA targeting, base editing (C-to-U and U-to-C), exon skipping, and translational enhancement, and is applied to pharmaceutical drug development (lead program EF-210 for Myotonic Dystrophy Type 1), agricultural seed development, and other biotechnology applications.

Product overview

EditForce is a biopharmaceutical company developing PPR (pentatricopeptide repeat) protein-based RNA editing technologies. The company's core product is the PPR Platform Technology, a programmable RNA editing system that enables sequence-specific binding to target RNA. This platform supports multiple therapeutic approaches including the RECODE technology for C-to-U editing, U-to-C editing technology, and the lead drug candidate EF-210 for Myotonic Dystrophy Type 1 (DM1) treatment using the CUG-PPR1 molecule delivered via AAV vectors.

Differentiator

Problem solved

Functional benefit

Products and services

  • PPR Platform Technology A programmable RNA editing platform based on PPR proteins that enables sequence-specific binding to target RNA. Supports multiple RNA manipulation modes including RNA binding, C-to-U base editing (RECODE), U-to-C editing, exon skipping, and translational enhancement from a single-protein architecture. Licensed to pharmaceutical companies for drug development.
  • RECODE Technology (RNA Editor for C-to-U with an Optimized DYW Enzyme) A proprietary C-to-U RNA editing technology combining a PPR protein that specifically binds to target RNA sequences with a DYW enzyme domain that converts cytidine (C) to uridine (U) in a single protein design. Enables precise base editing in animal cells and mice.
  • EF-210 Lead drug candidate: a recombinant AAV-based gene therapy for Myotonic Dystrophy Type 1 (DM1). Uses the CUG-PPR1 molecule that specifically binds to pathogenic CUG repeat RNA and blocks MBNL protein sequestration, restoring normal splicing activity and muscle function. Single IV dose demonstrated long-term efficacy in DM1 mouse model.

Quantifiable outcome

  • EF-210: Single IV dose in DM1 mouse model achieved maximum efficacy (no muscle stiffness observed even after 20 needle insertions) at doses of 1×10^13 vg/kg or higher (Day 56)
  • +2 more outcomes

Companies that use EditForce

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

EditForce technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

EditForce partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, major and minor.

  • 国立研究開発法人日本医療研究開発機構 (AMED)coreStrategic or Co-development Partner · 22 March 2023AMED (Japan Agency for Medical Research and Development) supports EditForce's drug development programs. EF-210 (DM1 treatment) was selected for AMED's 'Drug Discovery Venture Ecosystem Strengthening Project' (March 2023). Also selected in 2021 for 'RNA-targeted Drug Discovery Technology Development' under the Next-Generation Treatment/Diagnosis Realization Project.
  • 田辺三菱製薬株式会社 (Tanabe Mitsubishi Pharma)coreOEM/ Whitelabel/ Licensing Partner · 27 June 2022License agreement signed in June 2022 granting Tanabe Mitsubishi Pharma rights to research, develop, and commercialize gene therapy drugs using EditForce's PPR protein platform for specific CNS diseases. Combines EditForce's bio-pharmaceutical engineering capabilities with Tanabe Mitsubishi's global drug development expertise.
  • ソレイジア・ファーマ株式会社 (Solasia Pharma)majorStrategic or Co-development Partner · 26 December 2019Joint R&D agreement signed December 2019 for developing RNA editing-based cancer therapeutics. EditForce contributes PPR platform technology while Solasia contributes cancer drug development expertise. Multiple projects targeting different disease areas, RNA target sequences, and mechanisms of action.
  • 日本革新創薬株式会社 (Japan Innovation Pharmaceutical)minorStrategic or Co-development Partner · 11 July 2018Joint research agreement for age-related macular degeneration (AMD) drug development. EditForce designs and evaluates PPR proteins; Japan Innovation Pharmaceutical conducts animal model validation studies.
  • 広島大学 (Hiroshima University)coreTechnology or Integration · 1 July 2016Licensed DNA-targeting PPR technology from Hiroshima University (July 2016), providing EditForce with exclusive rights for DNA applications of PPR proteins, complementing the RNA rights from Kyushu University.
  • 九州大学 (Kyushu University)coreStrategic or Co-development Partner · 1 December 2015Founding partner institution. EditForce was established based on PPR protein research from Kyushu University Professor Takahiro Nakamura's laboratory. Signed joint research contract (December 2015) and exclusive patent license agreement (January 2016) for RNA PPR technology. Multiple co-development programs ongoing, including RECODE technology, EF-210, and structural studies published in Nature Communications (2026).

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

EditForce competitors and assessment

Company assessment

Direct peers

  • ProQR Therapeutics: Clinical-stage RNA editing company developing Axiomer RNA base-editing technology using ADAR enzymes. Targets similar genetic disease indications with platform approach, making it a direct competitor in programmable RNA editing therapeutics.
  • Wave Life Sciences: Clinical-stage RNA editing company using PRISM platform for oligonucleotide-based RNA base editing. Competes with EditForce in RNA-targeted therapeutics for genetic diseases, including neuromuscular disorders.
  • Korro Bio: Clinical-stage RNA editing company using ADAR-mediated RNA editing (OPERA platform). Targets liver and CNS indications with similar programmable RNA editing approach to EditForce's PPR technology.

Emerging players

  • AIRNA Bio: Emerging RNA editing company developing ADAR-based RNA editing therapeutics for genetic diseases. Competes with EditForce in the RNA editing modality with focus on liver-directed applications.
  • Ascidian Therapeutics: RNA editing company using RNA exon editing to address genetic diseases, including ophthalmology indications. Competes with EditForce's PPR-based exon skipping approach for genetic disease therapy.
  • Shape Therapeutics: RNA editing company using ADAR-based RNAfix platform and AAV delivery for in vivo RNA editing. Competes with EditForce in programmable RNA editing with similar AAV-delivery approach.
  • Locanabio: RNA-targeted therapeutic company developing RNA editing and RNA-binding protein-based therapies for genetic diseases. Overlaps with EditForce in programmable RNA-targeting approach for neuromuscular and rare diseases.

Broad incumbents

  • Beam Therapeutics: Clinical-stage base editing company with broader portfolio including DNA base editing and RNA base editing. While focused on DNA editing, their RNA editing programs compete with EditForce's PPR platform for partner and investor attention.
  • Mitsubishi Tanabe Pharma: Major Japanese pharmaceutical company and EditForce's CNS disease partner. Both share strategic interest in CNS and rare disease drug development using PPR platform, making it a strategic incumbent comparator.

Regional players

  • Solasia Pharma: Japanese specialty pharma company and EditForce's cancer co-development partner. Comparable as a Japan-focused pharma developing RNA editing-based cancer therapeutics using PPR platform technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

EditForce social profiles

Digital presence

EditForce financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EditForce leadership team

Management profile

Number of profiles

Profiles16 records

EditForce funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EditForce M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EditForce

What does EditForce do?

EditForce develops and licenses a proprietary PPR (Pentatricopeptide Repeat) protein-based platform technology for programmable RNA editing and manipulation. The platform enables sequence-specific RNA targeting, base editing (C-to-U and U-to-C), exon skipping, and translational enhancement, and is applied to pharmaceutical drug development (lead program EF-210 for Myotonic Dystrophy Type 1), agricultural seed development, and other biotechnology applications.

Is EditForce a public or private company?

EditForce is a private company. It is classified as venture growth investor backed and is currently operating.

When was EditForce founded?

EditForce was founded in 2015. It employs 1 to 10 people.

Where is EditForce based?

EditForce is headquartered in Fukuoka, Japan, in the Asia region.

How does EditForce make money?

Three revenue lines are on record. Licensing and Co-development Revenue is the primary driver. The others are PPR Platform Technology Provision and drug Development Pipeline.

Who are EditForce's main competitors?

Direct peers on record are ProQR Therapeutics, Wave Life Sciences and Korro Bio. Emerging players are AIRNA Bio, Ascidian Therapeutics, Shape Therapeutics and Locanabio. Broad incumbents are Beam Therapeutics and Mitsubishi Tanabe Pharma. Solasia Pharma is listed as a regional player.

Does EditForce have an API?

No public API is recorded for EditForce.

What industry is EditForce in?

EditForce's product category is RNA Editing Therapeutics & Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireEditForce demuestra la eficacia del tratamiento para la distrofia miotónica tipo 1EditForce, Inc. announced that a joint research study with Yamaguchi University and Osaka University demonstrated that a single administration of the jointly developed PPR protein CUG-PPR1 achieved long-term improvement of muscle symptoms in a mouse model of myotonic dystrophy type 1, with minimal immune response and side effects. The research findings were published in Science Translational Medicine on April 16, 2025, and represent a proof-of-concept for EditForce's proprietary PPR platform technology. The company indicated it will continue R&D efforts to bring the treatment to patients as soon as possible.PR NewswireEditForce réalise la technologie d'édition de l'ARN de « U-to-C »EditForce, Inc., a venture capital company originating from Kyushu University in Japan, has developed the world's first RNA editing technology capable of converting the base 'U' to 'C', and demonstrated its functionality in human cells through a joint study with Professor Takahiro Nakamura. This breakthrough addresses a critical gap in existing base editing technologies, which previously only supported C-to-U and A-to-G substitutions, opening possibilities for targeting mutations previously beyond reach. The company aims to leverage this technology to develop safer gene therapies by repairing mutations through RNA editing without altering the genomic sequence.PR NewswireEditForce realiza la tecnología de edición de ARN de "U a C"EditForce, Inc., a biotech company based in Fukuoka, Japan, has developed the world's first RNA base editing technology that converts "U" to "C" and demonstrated its functionality in human cells through a joint study with Professor Takahiro Nakamura at Kyushu University. The technology, published in the journal Communications Biology, enables editing of mutations that could not be targeted with existing technologies and is expected to contribute to R&D of therapies for genetic diseases. The company aims to leverage this innovation to establish safer gene therapies by improving the safety and efficacy of editing without altering the genome sequence.PR NewswireEditForce realisiert RNA-Editing-Technologie „U-zu-C"EditForce, Inc., a venture-capital-backed company originating from Kyushu University in Fukuoka, Japan, has implemented the world's first RNA editing technology capable of replacing base "U" with "C", demonstrated to function in human cells through a joint study with Professor Takahiro Nakamura. The technology enables the editing of mutations previously untargetable by existing RNA editing tools, offering a safer treatment approach without altering genomic sequences. EditForce plans to improve the safety and editing efficiency of this technology to establish innovative gene therapy platforms for various genetic diseases, with the study published in Communications Biology on September 15, 2022.PR NewswireEditForce Realizes RNA-editing Technology of "U-to-C"EditForce, Inc. has developed the world's first RNA-editing technology capable of changing uracil to cytosine bases in human cells, in collaboration with Professor Takahiro Nakamura from Kyushu University. This breakthrough expands the scope of treatable genetic diseases by addressing mutations previously inaccessible with existing base-editing methods. The study, published in Communications Biology, highlights potential for safer gene therapies that do not alter the genome sequence.BioSpaceEditForce Realizes RNA-editing Technology of “U-to-C”EditForce, a Kyushu University-originated venture, developed the world's first RNA-editing technology that changes U to C bases, demonstrated in human cells with Kyushu University. The study, published in Communications Biology, opens possibilities for editing gene mutations untargetable by existing technologies, potentially aiding therapies for genetic diseases.PR NewswireEditForce Realizes RNA-editing Technology of "U-to-C"EditForce, Inc., a biotech company based in Fukuoka, Japan, has developed the world's first RNA-editing technology enabling base substitution from "U" to "C," demonstrating its functionality in human cells through a joint study with Professor Takahiro Nakamura at Kyushu University. The technology, published in the journal Communications Biology in September 2022, enables editing of gene mutations that could not previously be targeted with existing technologies. The company plans to improve safety and editing efficiency to establish this as a novel gene therapy approach for treating genetic diseases.